Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 11/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.37 |
| ▸ | CASP1 | P29466 | 4/20 | 0.37 |
| ▸ | CASP7 | P55210 | 4/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 2/20 | 0.37 |
| ▸ | TTK | P33981 | 2/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.35 |
| ▸ | USP2 | O75604 | 3/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.34 |
| ▸ | CCND1 | P24385 | 1/20 | 0.34 |
| ▸ | CCND2 | P30279 | 1/20 | 0.34 |
| ▸ | CCND3 | P30281 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30278828 | 1.00 | KDM4E (0.38) | KDM4EPKMCYP1A2ALDH1A1HSD17B10 | |
| SCHEMBL31532102 | 0.80 | CYP1A2 (0.58) | KDM4EPKMCYP1A2ALDH1A1HSD17B10 | |
| SCHEMBL5264817 | 0.79 | CDK4 (0.54) | PIM1TTKPIM2CDK4CCND1 | |
| SCHEMBL29991137 | 0.79 | CDK4 (0.54) | PIM1TTKPIM2CDK4CCND1 | |
| SCHEMBL17807800 | 0.78 | CYP1A2 (0.39) | CYP1A2ALDH1A1HSD17B10CASP1CASP7 | |
| SCHEMBL22200718 | 0.78 | MTOR (0.40) | KDM4ECYP1A2ALDH1A1HSD17B10CASP1 | |
| SCHEMBL22190717 | 0.78 | CYP1A2 (0.39) | CYP1A2ALDH1A1HSD17B10CASP1CASP7 | |
| SCHEMBL1318966 | 0.75 | CDK4 (0.47) | KDM4EALDH1A1PIM1TTKPIM2 | |
| SCHEMBL30879077 | 0.74 | PIM1 (0.39) | PIM1TTKPIM2CDK4CCND1 | |
| SCHEMBL23507970 | 0.72 | USP1 (0.41) | PIM1TTKPIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559505-B2 | IDH mutant inhibitor and use thereof | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2026-02-24 | — | — | US | disclosed |
| EP-3941919-B1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. | GENENTECH INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12344603-B2 | Pyrido-pyrimidinone and pteridinone compounds and methods of use | GENENTECH, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20230174550-A1 | IDH MUTANT INHIBITOR AND USE THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2023-06-08 | — | — | US | disclosed |
| US-20230174550-A1 | IDH MUTANT INHIBITOR AND USE THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2023-06-08 | — | — | US | disclosed |
| US-20230174550-A1 | IDH MUTANT INHIBITOR AND USE THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2023-06-08 | — | — | US | disclosed |
| CN-115768775-A | IDH mutant inhibitor and application thereof | 微境生物医药科技(上海)有限公司 | 2023-03-07 | — | — | CN | disclosed |
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | PARAZA PHARMA, INC. (CA) | 2023-02-16 | — | — | US | disclosed |
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | PARAZA PHARMA, INC. (CA) | 2023-02-16 | — | — | US | disclosed |
| EP-3941919-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES | Genentech, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| WO-2022001916-A1 | IDH MUTANT INHIBITOR AND USE THEREOF | 微境生物医药科技(上海)有限公司 | 2022-01-06 | — | — | WO | disclosed |
| CN-113508115-A | Pyridopyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol requiring enzyme I (IRE I A) for the treatment of cancer diseases | 基因泰克公司 | 2021-10-15 | — | — | CN | disclosed |
| WO-2020142612-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. | GENENTECH, INC. (US) | 2020-07-09 | — | — | WO | disclosed |
| WO-2020142612-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. | GENENTECH, INC. (US) | 2020-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559505-B2 | IDH mutant inhibitor and use thereof | IDH3A, IDH1, IDH3B | KDM4E 470/4885PKM 1010/4885CYP1A2 698/4885 |
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | TYMP, TYMS, DPYD | KDM4E 2139/4885PKM 44/4885CYP1A2 1312/4885 |
| US-20230174550-A1 | IDH MUTANT INHIBITOR AND USE THEREOF | IDH1, IDH3A, IDH3B | KDM4E 546/4885PKM 2019/4885CYP1A2 1269/4885 |
| US-12344603-B2 | Pyrido-pyrimidinone and pteridinone compounds and methods of use | TYMP, TYMS, DPYD | KDM4E 2139/4885PKM 44/4885CYP1A2 1312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.